Babol University of Medical Sciences Caspian Journal of Surgery 3115-9087 1 2 2025 06 01 Thrombocytopenia and Its Impact on Bleeding Risk During Chemotherapy Port Placement: A Comparative Study 85 90 727921 10.22088/caspjs.2025.2064862.1023 EN Maryam Parsa Student Research Committee, Babol University of Medical Sciences, Babol University of Medical Sciences, Babol, Iran. 0009-0006-3960-6351 Pouya Tayebi Department of Vascular and Endovascular Surgery, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran. 0000-0002-6923-0221 Majid Nabipour Department of Hematology & Oncology, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran. 0000-0001-6224-5036 Fatemeh Farsiani Student Research Committee, Babol University of Medical Sciences, Babol University of Medical Sciences, Babol, Iran. 0009-0003-7157-8504 Ali Bijani Social Determinant of Health Research Center, Babol University of Medical Sciences, Babol, Iran. 0000-0003-2233-8726 Journal Article 2025 07 05 Background: Thrombocytopenia, a common condition in cancer patients undergoing chemotherapy, presents significant challenges in medical procedures, particularly in central venous port placement, due to the elevated risk of bleeding.<br><br>Methods: This study involved 100 cancer patients undergoing chemotherapy port placement, divided into two groups: 50 patients with thrombocytopenia (platelet count <150,000/μL) and 50 without. Bleeding complications were assessed and compared between the two groups. Laboratory data, including platelet counts and coagulation parameters, were analyzed, and statistical comparisons were made using chi-square and t-tests.<br><br>Results: The incidence of bleeding complications was significantly higher in the thrombocytopenic group (12%) compared to the non-thrombocytopenic group (2%) (p = 0.050). Hematoma formation was observed in 4% of patients, with a higher occurrence in the thrombocytopenic group (6%) versus the non-thrombocytopenic group (2%), although this difference was not statistically significant (p = 0.307). Ecchymosis occurred in 3% of patients, all in the thrombocytopenic group (p = 0.079). Patients with severe thrombocytopenia (platelet count < 50,000/μL) had a significantly higher risk of active bleeding, with a notable association between platelet count and bleeding (p = 0.034).<br><br>Conclusion: Thrombocytopenic patients, particularly those with severe thrombocytopenia, face an increased risk of bleeding during chemotherapy port placement. Ultrasound-guided techniques, along with preoperative management strategies, can effectively minimize bleeding risks. https://www.caspjs.com/article_727921_81bfe154763ca08c54c4e78db736eb7e.pdf